Published this week as part of ecancer’s online educational program, renowned leaders in oncology including VHIO’s Enriqueta Felip, Principal Investigator of our Thoracic Tumors Group, were invited to participate in a virtual Zoom panel discussion on The Latest in EGFR-positive NSCLC with exon 20 insertion mutations.
Chaired by Sanjay Popat (The Royal Marsden Hospital, London, UK), Enriqueta joined the other invited experts Michael Thomas (University of Heidelberg, Heidelberg, Germany), Marina Garassino (Istituto Nazionale dei Tumori Cancer Institute, Milan, Italy), and Rosario Campelo (University of A Coruña, A Coruña, Spain), to debate and exchange on the very latest approaches and treatment options available for the management of patients with EGFR mutant non-small cell lung cancer.
They explore current treatment paradigms, the promise of novel therapies that have been recently making the headlines including amivantamab and mobocertinib, as well as poziotinib, and the efficacy of osimertinib. Mention is also made of some of the breaking studies that were recently presented at the 2020 virtual World Conference on Lung Cancer (WCLC). This annual, worldwide meeting is organized by the International Association for the Study of Lung Cancer (IASLC), for which VHIO’s Enriqueta Felip currently serves as Secretary on its Board of Directors (2019-2021).
This superb panel discussion concludes by their signposting of future directions in the treatment and management of this patient population.
To access and view the session please visit: https://ecancer.org/en/video/9491-latest-in-egfr-positive-nsclc-with-exon-20-insertion-mutations.
